[Protective effects of losartan against myocardial ischemic reperfusion in intact canine].
To evaluate the protective effect of losartan, an angiotensin II type 1 (AT1) receptor antagonist, against myocardial ischemic reperfusion in intact canine. Sixteen dogs were divided into model group(n=8) with left anterior descending coronary artery occlusion for 30 min followed by reperfusion for 30 min and losartan group (n=8) with 5 mg/(kg x d) intragastric losartan administration for 2 weeks before the ischemic-reperfusion model establishment. Monophasic action potential recording technique was employed to observe the incidence of early after depolarization (EAD) and reperfusion arrhythmias. In the model group, 5 dogs (62.5%) developed EAD and reperfusion arrhythmia while 3 (37.5%) developed the symptoms in losartan group, showing significant difference between the two groups (P<0.05). No ventricular tachycardia or ventricular fibrillation was observed in losartan group (P<0.01). Losartan can suppress the occurrence of EAD during reperfusion following myocardial ischemia to reduce the incidence of reperfusion arrhythmias, suggesting its protective effect against myocardial ischemic injury.